Lung Cancer-Targets and Therapy

Scope & Guideline

Pioneering Insights in Lung Cancer Mechanisms

Introduction

Immerse yourself in the scholarly insights of Lung Cancer-Targets and Therapy with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN-
PublisherDOVE MEDICAL PRESS LTD
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationLUNG CANCER-TARGETS / Lung Cancer-Targets Ther.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND

Aims and Scopes

The journal 'Lung Cancer-Targets and Therapy' is dedicated to advancing the understanding and treatment of lung cancer through innovative research and clinical studies. Its primary focus lies in the integration of targeted therapies, immunotherapy, and novel treatment strategies for various lung cancer subtypes.
  1. Targeted Therapies for Lung Cancer:
    The journal emphasizes research on targeted therapies for lung cancer, particularly focusing on genetic mutations (e.g., EGFR, ALK, MET) and the development of drugs that specifically target these mutations.
  2. Immunotherapy Advances:
    A significant focus is on the advancements in immunotherapy for lung cancer, analyzing the efficacy and mechanisms of immune checkpoint inhibitors and other immunotherapeutic approaches.
  3. Clinical Trials and Translational Research:
    The journal frequently publishes results from clinical trials and translational research studies that evaluate new therapeutic options and their impacts on patient outcomes.
  4. Molecular Biology and Genetics of Lung Cancer:
    Research related to the molecular and genetic underpinnings of lung cancer, including biomarker discovery and the role of genetic alterations in treatment response, is a core area of interest.
  5. Novel Diagnostic Techniques:
    The journal also covers innovative diagnostic approaches such as liquid biopsies and whole exome sequencing, which are crucial for early detection and personalized treatment plans.
The journal has seen a rise in certain themes that reflect the evolving landscape of lung cancer research. These emerging topics are indicative of advancements in treatment strategies and an increased understanding of lung cancer biology.
  1. Targeted Therapies for Specific Mutations:
    Recent publications have increasingly focused on targeted therapies for specific mutations, such as KRAS and MET alterations, highlighting the importance of precision medicine in lung cancer treatment.
  2. Combination Therapies:
    There is a growing trend towards investigating combination therapies that integrate targeted agents with immunotherapies or other treatment modalities, aiming to enhance efficacy and overcome resistance mechanisms.
  3. Liquid Biopsy and Biomarker Research:
    The rise in liquid biopsy studies reflects an emerging emphasis on non-invasive diagnostic methods and real-time monitoring of treatment responses, which are becoming crucial in personalized lung cancer care.
  4. Immunotherapy for Early-Stage Disease:
    Emerging research is focusing on the application of immunotherapy in early-stage lung cancer, particularly in the neoadjuvant and adjuvant settings, which indicates a shift towards earlier intervention strategies.
  5. Understanding Resistance Mechanisms:
    There is an increasing interest in exploring mechanisms of resistance to targeted therapies and immunotherapies, which is vital for developing next-generation treatments that can effectively address these challenges.

Declining or Waning

While 'Lung Cancer-Targets and Therapy' continues to thrive in many research areas, certain themes have become less prominent in recent publications. This decline may reflect shifts in research focus or advancements in understanding specific aspects of lung cancer.
  1. Traditional Chemotherapy Approaches:
    There has been a noticeable decrease in publications focusing on traditional chemotherapy regimens, as research increasingly shifts towards targeted therapies and immunotherapies that offer more personalized treatment options.
  2. Generalized Lung Cancer Treatments:
    Research articles that discuss generalized or non-specific treatment approaches are appearing less frequently, with a preference for studies that delve into targeted and individualized therapies based on specific genetic profiles.
  3. Older Biomarker Studies:
    The exploration of older biomarkers without consideration of newer genomic insights is waning, as the field moves towards more sophisticated biomarker analyses that incorporate the latest genetic research.

Similar Journals

Cancer Research Communications

Empowering global collaboration in cancer research.
Publisher: AMER ASSOC CANCER RESEARCHISSN: Frequency: 1 issue/year

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

World Journal of Gastrointestinal Oncology

Unveiling insights that shape the future of gastrointestinal oncology.
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 1948-5204Frequency: 12 issues/year

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

Cancers

Unleashing insights to combat cancer effectively.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

Targeted Oncology

Empowering researchers to redefine cancer treatment.
Publisher: SPRINGERISSN: 1776-2596Frequency: 6 issues/year

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.

Clinical Lung Cancer

Elevating standards in oncology and respiratory health.
Publisher: CIG MEDIA GROUP, LPISSN: 1525-7304Frequency: 6 issues/year

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

ANNALS OF ONCOLOGY

Empowering discoveries in oncology and hematology.
Publisher: ELSEVIERISSN: 0923-7534Frequency: 12 issues/year

ANNALS OF ONCOLOGY, published by Elsevier, stands as a premier journal in the field of oncology, hematology, and general medicine, with a notable impact factor that underscores its significance in advancing cancer research and clinical practice. Established in 1990, this journal has become a highly respected source of information, consistently ranked in the Q1 category in its respective fields, showcasing its influence and credibility (Rank #4/404 in Oncology and Rank #2/137 in Hematology as per Scopus rankings). With a focus on innovative therapies, clinical trials, and emerging research, ANNALS OF ONCOLOGY serves as an essential resource for researchers, clinicians, and students dedicated to unraveling the complexities of cancer treatment and care. Although offering restricted access options, its impactful studies and discoveries continue to shape the future of oncology.

INTERNATIONAL JOURNAL OF CANCER

Connecting researchers to the latest in cancer advancements.
Publisher: WILEYISSN: 0020-7136Frequency: 24 issues/year

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

LUNG CANCER

Elevating Cancer Research to New Heights
Publisher: ELSEVIER IRELAND LTDISSN: 0169-5002Frequency: 12 issues/year

LUNG CANCER, published by Elsevier Ireland Ltd, is a pivotal academic journal dedicated to advancing knowledge in the fields of Cancer Research, Oncology, and Pulmonary and Respiratory Medicine. With an impressive impact factor reflected by its Q1 ranking across three key categories for 2023, this journal occupies a prestigious position within the research community, emphasizing quality and significance in published works. Since its inception in 1985, LUNG CANCER has provided a comprehensive platform for researchers and clinicians to disseminate findings and novel insights, enhancing the understanding and treatment of lung cancer. The journal stands out with Scopus rankings, placing it in the top percentile across multiple relevant fields, including a notable rank of #20 in Pulmonary and Respiratory Medicine. By fostering collaboration among scholars, the journal aims to facilitate innovative research and promote evidence-based practices that could transform patient outcomes. As such, LUNG CANCER is an essential resource for those navigating this complex area of study, from seasoned researchers to aspiring professionals.

npj Precision Oncology

Leading the Charge in Precision Oncology Research
Publisher: NATURE PORTFOLIOISSN: Frequency: 1 issue/year

npj Precision Oncology, an esteemed peer-reviewed journal published by NATURE PORTFOLIO, stands at the forefront of oncological research and precision medicine. Launched as an Open Access platform in 2017, this journal not only facilitates the dissemination of innovative research findings but also ensures that crucial insights are freely accessible to the global scientific community. With an impressive ranking of Q1 in both Cancer Research and Oncology, and a commendable Scopus rank that places it in the top 15% of its field, npj Precision Oncology is dedicated to advancing our understanding of personalized cancer therapies through high-quality research. Catering to professionals, researchers, and students alike, this journal aims to bridge the gap between laboratory science and clinical application, paving the way for transformative approaches in oncology. As the landscape of cancer treatment evolves, npj Precision Oncology remains a crucial platform for fostering collaboration and sparking ideas that can significantly impact patient care.

ONCOLOGY RESEARCH

Uncovering New Horizons in Cancer Science
Publisher: TECH SCIENCE PRESSISSN: 0965-0407Frequency: 6 issues/year

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.